The objectives of this phase I trial were to determine the maximally tolerated doses of the combination of epirubicin and paclitaxel with and without G-CSF (granulocyte colony stimulating factor) support and to investigate whether epirubicin pharmacokinetics are altered by paclitaxel. Patients with advanced cancer, performance status 0–2, and a normal left ventricular ejection fraction who had received up to 1 prior chemotherapy regimen were treated with epirubicin followed by a 3-hour infusion of paclitaxel repeated every 3 weeks. Dose levels studied were (paclitaxel/epirubicin) 155/75, 175/75, 175/90, 200/90 mg/m2 without G-CSF and 175/90 mg/m2 with G-CSF. Thirty-five patients were entered and all were assessable for toxicity. The dose-limiting dose level was 175 mg/m2 paclitaxel and 90 mg/m2 epirubicin with limiting toxicities of febrile neutropenia, diarrhea and esophagitis. The addition of G-CSF did not allow escalation of epirubicin. No significant cardiac toxicity was observed. Epirubicin pharmacokinetics were studied during the first 2 cycles in 6 patients, who were randomized to receive 1 cycle with no interval between the completion of the epirubicin and the commencement of the paclitaxel infusion and the other cycle with a 72-hour interval between the drugs. There was no substantial effect of paclitaxel on epirubicin or epirubicinol pharmacokinetics, although there was a marginal increase in glucoronidation. In conclusion, paclitaxel 175 mg/m2 and epirubicin 75 mg/m2 is recommended for phase II and III studies.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Seidman AD, Reichman BS, Crown JPA et al.: Paclitaxel as second and subsequent therapy for metastatic breast cancer: Activity independent of prior anthracycline response. J Clin Oncol 13: 1152–1159, 1995
Holmes FA, Madden T, Newman RA et al.: Sequencedependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. J Clin Oncol 14: 2713–2721, 1996
Fisherman JS, Cowan KS, Noone K et al.: Phase I- II study of 72-hour infusional paclitaxel and doxorubicin with granulocyte-stimulating-factor in patients with metastatic breast cancer. J Clin Oncol 14: 774–782, 1996
Sledge GW Jr, Robert M, Sparano JA et al.: Paclitaxel (taxol)-doxorubicin combinations in advanced breast cancer: The Eastern Cooperative Oncology Group experience. Sem Oncol 21 (Suppl 8): 15–18, 1994
Gianni L, Munzone E, Capri G et al.: Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13: 2688–2699, 1995
Gianni L, Vigano L, Locatelli A, Capri G, Giani A, Tarenzi E, Bonadonna G et al.: Human pharmacokinetic characterisation and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. J Clin Oncol 15(5): 1906–1915, 1997
Berg SL, Cowan KH, Bolis FM et al.: Pharmacokinetics of taxol and doxorubicin administered alone and in combination by continuous 62-hour infusion. J Natl Cancer Inst 86: 143–145, 1994
Webster LK, Cosson EJ, Stokes KH, Millward MJ: Effect of the paclitaxel vehicle, Cremophor EL, on the pharmacokinetics of doxorubicin and doxorubicinol in mice. Br J Cancer 73: 522-524, 1996
Rischin D, Millward M, Webster L, Tinnelly K, Toner G, Bishop J et al.: Phase I trial of Cremophor EL and doxorubicin in patients with advanced cancer. Anticancer Drugs 5 (Suppl 1): 43–44, 1994
Bonadonna G, Gianni L, Santoro A et al.: Drugs ten years later: Epirubicin. Ann Oncol 4: 359–369, 1993
Zhang W, Zalcberg J, Cosolo W: Interaction of epirubicin with other cytotoxics and anti-emetic drugs. Anticancer Drugs 3: 593–597, 1992
Conte PF, Baldini E, Gennari A, Michelotti A, Salvadori B, Tibaldi C, Danesi R, Innocenti F, Gentile A, Dell'Anna R, Biadi O, Mariani M, Del Tacca M: Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: A regimen with high activity and low cardiotoxicity in advanced breast cancer. J Clin Oncol 15(7): 2510–2517, 1997
Luck HJ, Thomssen C, du Bois A, Lisboa BW, Untch M, Kuhnle H, Janicke F, Meerpohl HG, Lindner C, Konecny G, Hecker D, Diegarten K: Preliminary results of a phase II study of epirubicin and paclitaxel as first-line treatment in patients with metastatic breast cancer. Sem Oncology 24(1) (Suppl 3): S3-13–S3-16, 1997
Spielmann M, Catimel G, Bourgeois H, Pouillart P, Llombart-Cussac A, Rhor-Alvarado A, Le Grand A, Graffand N, Pellae-Cosset B: Taxol and farmorubicin in metastatic breast cancer: Preliminary results of phase I study. Ann Oncol 7 (Suppl 5), 1996
Gehl J, Boesgard M, Paaske T et al.: Combined doxorubicin and paclitaxel in advanced breast cancer: Effective and cardiotoxic. Ann Oncol 7: 687–693, 1996
Gianni L, Dombernowsky P, Sledge G, Amadori M, Martin M, Baynes R, Arbuck S, Weil C, Tuck M, Messina M, Winograd B: Cardiac function following combination therapy with taxol and doxorubicin for advanced breast cancer. Proc ASCO 444, 1998
Gianni L, Bigano L, Locatelli A, Giani A, Capri G, Bertuzzi A, Grasselli G, Tarenzi E, Bonadonna G: Different interference of paclitaxel (PTX) on human pharmacokinetics of doxorubicin (DOX) and epirubicin (EPI). Proc ASCO 16, 1997
Conte PF, Gennari A: Anthracyclines-paclitaxel combinations in the treatment of breast cancer. Ann Oncol 8: 939–943, 1997
About this article
Cite this article
Rischin, D., Webster, L.K., Millward, M.J. et al. A phase I and pharmacokinetic study of paclitaxel and epirubicin in advanced cancer. Invest New Drugs 17, 73–80 (1999). https://doi.org/10.1023/A:1006219601797